Results 41 to 50 of about 7,686 (201)

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. [PDF]

, 2018
AimsThis analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using pooled data from 10 phase 3 ODYSSEY trials.Materials and methodsData ...
Bujas-Bobanovic, Maja, Ginsberg, Henry N, Henry, Robert R, Letierce, Alexia, Louie, Michael J, Müller-Wieland, Dirk, Taub, Pam R   +6 more
core   +1 more source

A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels

Upsala Journal of Medical Sciences
Background: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials.
Maria K. Svensson, Stefan James, Annica Ravn-Fischer, Guillermo Villa, Lovisa Schalin, Thomas Cars, Stefan Gustafsson, Emil Hagström   +7 more
doaj   +1 more source

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Lipids, EarlyView.
ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao, Nuan Wang, Di Shi, Hao Zhou, Dan Chen, Guofang Chen   +5 more
wiley   +1 more source

Outcome-based pricing for new pharmaceuticals via rebates [PDF]

, 2020
The price of new brand-name prescription drugs has been rising fast in the United States. For example, the Amgen cholesterol drug Repatha had an initial list price of $14,523 per year.
Adida, E
core  

Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes:A systematic review and meta-analysis [PDF]

, 2019
Background: To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on major adverse cardiovascular events (MACE).Methods: Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in ...
Du, Heyue, Gao, Haihui, Hao, Xiaoting, Kwong, Joey S. W., Lang, Chim, Li, Jianshu, Li, Ling, Li, Qianrui, Li, Sheyu, Li, Xiaodan, Mordi, Ify, Nemeth, Imola, Rao, Li, Su, Na, Tian, Haoming, Vandvik, Per Olav, Yang, Xueli, Zhang, Longhao   +17 more
core   +3 more sources

High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases

The FEBS Journal, EarlyView.
High serum cholesterol is linked to colorectal cancer liver metastases (CRCLM) subtypes with poor survival (replacement pattern). Levels of cholesterol under 4 mmol·L−1 correlated with better survival and a desmoplastic pattern subtype. Furthermore, in vivo PCSK9 inhibitor evolocumab, which lowers cholesterol, reduced liver metastases.
Amatzia Gantz, Audrey Kapelanski‐Lamoureux, Miran Rada, Lucyna Krzywon, Migmar Tsamchoe, Anastasia Tsatoumas, Stephanie K. Petrillo, Nabil G. Seidah, Anthoula Lazaris, Peter Metrakos   +9 more
wiley   +1 more source

Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial

Trials, 2022
Background Despite advances in surgical and postoperative care, myocardial injury or infarction (MI) is still a common complication in patients undergoing coronary artery bypass surgery (CABG).
Hye Rim Na, O Sung Kwon, Joon Kyu Kang, Yong Han Kim, Ju Yong Lim   +4 more
doaj   +1 more source

Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk [PDF]

, 2016
Control of lipid levels is one of the most effective strategies for cardiovascular (CV) event prevention. In fact, many clinical trials have clearly demonstrated that low-density lipoprotein cholesterol (LDL-C) lowering, primarily with statins, reduces ...
AGABITI ROSEI, Enrico, SALVETTI, Massimo
core   +1 more source

Disrupting Lipid Raft Microdomains to Block Polyploid Giant Cancer Cell Budding and Enhance Radiotherapy Response

Advanced Science, Volume 13, Issue 9, 13 February 2026.
Radiation induces polyploid giant cancer cells (PGCCs) that regenerate tumors through virus‐like budding. This process depends on a SNCG–FLOT2–CHMP4B signaling axis functioning in lipid raft microdomains. Disrupting these domains using statins or anti‐PCSK9 antibodies blocks PGCC budding, suppresses tumor repopulation, and enhances radiotherapy ...
Zheng Deng, Haoran Sun, Jin Cheng, Ruyi Zhao, Jianzhu Xie, Yanwei Song, Yucui Zhao, Chenwei Lin, Binjie Hu, Yanping Gong, Jun Lin, Sijia He, Yuntao Luo, Minghui Zhao, Yiwei Wang, Ming Jiao, Yuqin Yang, Jikun Li, Shujie Xia, Chuanyuan Li, Qian Huang   +20 more
wiley   +1 more source

Efficacy and tolerability of evolocumab vs. ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial

, 2016
Importance: Muscle-related statin intolerance is reported by 5% to 20% of patients. Objective: To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and ...
, Ballantyne, Christie M, Brennan, Danielle M, Bruckert, Eric, Ceška, Richard, Dent-Acosta, Ricardo E, Elliott, Mary, Gouni-Berthold, Ioanna, Jensen, Henrik Kjærulf, Jeppesen, Jørgen, Lehman, Sam J, Lepor, Norman, Nissen, Steven E, Preiss, David, Rosenson, Robert S, Sattar, Naveed, Scott, Rob, Somaratne, Ransi, Stein, Evan A, Stroes, Erik, Wasserman, Scott M   +20 more
core   +2 more sources